 |
|
Nephrogenic Systemic FibrosisRelationship to Gadolinium and Response to Photopheresis
Heather Richmond, BA;
Jeffrey Zwerner, MD, PhD;
Youn Kim, MD;
David Fiorentino, MD, PhD
Arch Dermatol. 2007;143(8):1025-1030.
Background Nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, is an idiopathic condition seen in patients with renal disease that is characterized by cutaneous sclerosis that can often result in contractures, pain, and functional disability as well as systemic complications. Recent reports have suggested a possible link with exposure to gadolinium, a commonly used radiocontrast agent. No current therapy has clearly demonstrated efficacy for NSF, although case reports suggest that extracorporeal photopheresis (ECP) may be of benefit. The purpose of this study was to explore the plausibility of a gadolinium linkage with NSF as well as to assess the efficacy of ECP in the treatment of a cohort of patients with NSF.
Observations We report our experience with 8 consecutive patients with NSF seen at the Stanford Medical Center, Palo Alta, California, from 2004 to 2006. Of the 8 patients, 6 had a history of arterial or venous thrombotic disease and 7 had a documented exposure to gadolinium within 1 week to several months prior to the onset of NSF. Specifically, all patients were exposed to gadodiamide. We treated 5 of the patients with ECP. After a mean number of 34 treatment sessions over a mean of 8.5 months, 3 patients experienced a mild improvement in skin tightening, range of motion, and/or functional capacity.
Conclusions Our data support the hypothesis that exposure to gadolinium, perhaps specifically gadodiamide, plays a role in the pathogenesis of NSF. Larger epidemiologic studies will be needed to confirm this association. In addition, our experience suggests that, if used for extended periods, ECP might have some mild benefit for patients with NSF. Larger, randomized, placebo-controlled trials of ECP should be performed to more specifically assess the benefit of ECP in the treatment of NSF.
Author Affiliations: Department of Dermatology, Stanford University School of Medicine, Palo Alto, California.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Case 37-2009 -- A 46-Year-Old Woman with Chronic Renal Failure, Leg Swelling, and Skin Changes
Kroshinsky et al.
NEJM 2009;361:2166-2176.
FULL TEXT
Detection of Clonal T Cells in the Circulation of Patients With Nephrogenic Systemic Fibrosis
Kreuter et al.
Arch Dermatol 2009;145:1164-1169.
ABSTRACT
| FULL TEXT
UV-A1 Therapy for Nephrogenic Systemic Fibrosis
Tran et al.
Arch Dermatol 2009;145:1170-1174.
ABSTRACT
| FULL TEXT
Estimates of Risk, Empirical Treatment Observations, and Unexpected Laboratory Findings Reveal the Complexity of Nephrogenic Systemic Fibrosis
High
Arch Dermatol 2009;145:1178-1182.
FULL TEXT
Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis
Agarwal et al.
Nephrol Dial Transplant 2009;24:856-863.
ABSTRACT
| FULL TEXT
Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction
Kay
Ann Rheum Dis 2008;67:iii66-iii69.
ABSTRACT
| FULL TEXT
Limited Effects of UV-A1 Phototherapy in 3 Patients With Nephrogenic Systemic Fibrosis
Kreuter et al.
Arch Dermatol 2008;144:1527-1529.
FULL TEXT
MRI Safety Update 2008: Part 1, MRI Contrast Agents and Nephrogenic Systemic Fibrosis
Shellock and Spinazzi
Am. J. Roentgenol. 2008;191:1129-1139.
ABSTRACT
| FULL TEXT
Case 6-2008 -- A 46-Year-Old Woman with Renal Failure and Stiffness of the Joints and Skin
Kay et al.
NEJM 2008;358:827-838.
FULL TEXT
|
